Piramal Life Sciences has started the first phase of trail of its diabetes-metabolic drug in Canada. Health Canada has already given approval for the trails.

Piramal Life Sciences said: "The company has commenced phase I trail of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada."

Company further said P2202 is the second compound from Eli Lilly & Co and is part of the collaborative agreement between the two companies and is being developed for diabetes-metabolic syndrome.

Piramal Managing Director Somesh Sharma said: "This is our eighth entity to enter the clinic and third for diabetes-metabolic disorders and bears testimony to our efforts to build a diversified and strong pipeline of products to address unmet medical needs in this important therapeutic segment."